<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00612014</url>
  </required_header>
  <id_info>
    <org_study_id>TZP-101-CL-G004</org_study_id>
    <secondary_id>2007-003279-38</secondary_id>
    <nct_id>NCT00612014</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-ranging Study to Assess the Efficacy and Safety of TZP-101 When Administered as a 30 Minute I.V. Infusion to Subjects With Severe Gastroparesis Due to Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tranzyme, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tranzyme, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether TZP-101 is effective in the treatment of
      symptomatic gastroparesis due to diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects are randomized according to an adaptive randomization procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the mean Gastroparesis Cardinal Symptom Index score (24 hour recall version) across the four days of dosing. Baseline is the average of the scores collected across the 4 days just prior to admission for dosing.</measure>
    <time_frame>after 4 dosing days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative GSA score after each dosing event and after all dosing events</measure>
    <time_frame>every 30 minutes for 4 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Gastroparesis</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 micrograms/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 micrograms/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>160 micrograms/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>320 microgram/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 microgram/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5% dextrose in water</intervention_name>
    <description>60 ml IV infusion over 30 minutes</description>
    <arm_group_label>1</arm_group_label>
    <other_name>D5W</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TZP-101</intervention_name>
    <description>40 micrograms/kg iv 2ml/minute for 30 minutes
1 infusion/day for 4 consecutive days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TZP-101</intervention_name>
    <description>80 micrograms/kg iv 2ml/minute for 30 minutes
1 infusion/day for 4 consecutive days</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TZP-101</intervention_name>
    <description>160 micrograms/kg iv 2ml/minute for 30 minutes
1 infusion/day for 4 consecutive days</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TZP-101</intervention_name>
    <description>320 micrograms/kg iv 2ml/minute for 30 minutes
1 infusion/day for 4 consecutive days</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TZP-101</intervention_name>
    <description>600 micrograms/kg iv 2ml/minute for 30 minutes
1 infusion/day for 4 consecutive days</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has type 1 or type 2 diabetes mellitus

          -  Subject has documented diagnosis of gastroparesis (all of the following apply):

               -  Confirmed delayed gastric emptying (see Appendix IV; properly conducted gastric
                  emptying assessments within last 6 months acceptable)

               -  AND a minimum 3 month history of relevant symptoms for gastroparesis (chronic
                  postprandial fullness, bloating, epigastric discomfort, early satiety, belching
                  after meal, postprandial nausea, vomiting).

               -  AND a mean Gastroparesis Cardinal Symptom Index (GCSI) Score (2 week recall
                  version) of ≥ 2.66

               -  AND it is confirmed by endoscope that there are no obstructive lesions in the
                  esophagus or stomach (endoscopy within prior 3 months acceptable)

          -  Subject has never had a gastrectomy, nor major abdominal surgery or any evidence of
             bowel obstruction within the previous 12 months

          -  Dosage of any concomitant medications has been stable for at least 3 weeks

          -  HbA1c level is ≤ 10.0%

          -  Subject has a BMI &lt; 30

          -  Subject body weight is ≤ 100 kg

          -  If female, post-menopausal for the past 12 months, surgically sterile (i.e. tubal
             ligation, hysterectomy), or using an adequate method of birth control (i.e., oral
             contraceptives, double barrier method, IUD cover) or sterilized partner

        Exclusion Criteria:

          -  Subject has acute severe gastroenteritis

          -  Subject has a gastric pacemaker

          -  Subject is on chronic parenteral feeding

          -  Subject has daily persistent severe vomiting

          -  Subject has pronounced dehydration

          -  Subject has had diabetic ketoacidosis in last 4 weeks

          -  Subject has a history of eating disorders (anorexia nervosa, binge eating, bulimia)

          -  Subject has a marked baseline prolongation of QT/QTc interval (repeated demonstration
             of a QTc interval &gt;450 ms for male / &gt;470 ms for female)

          -  Subject has a history of additional risk factors for Torsades de Pointes (heart
             failure, chronic hypokalemia, family history of Long QT Syndrome)

          -  Subject requires use of concomitant medication that prolongs the QT interval

               -  List provided to clinical sites

          -  Subject has history of cardiovascular ischemia in previous 12 months or acute
             myocardial infarction (MI) or unstable angina

          -  Subject requires use of concomitant medication that is known to interact with
             isoenzyme CYP3A4 and the combination with an CYP3A4 inhibitor is known to introduce a
             clinically significant drug interaction

               -  List provided to clinical sites

          -  Subject has a history of psychiatric disorder or cognitive impairment that would
             interfere with participation in the study

          -  Subject has a history of alcoholism

          -  Subject is taking regular daily narcotics

          -  Subject has a known history of Hep B, Hep C or HIV

          -  Subject has severely impaired renal function (creatinine clearance &lt; 30 mL/min)

          -  Subject has severe impairment of liver function, defined as albumin level ≤ 2.5 gm/dL
             and/or prothrombin time &gt;6 seconds over control (INR &gt; 2.3)

          -  Subject has participated in an investigational study within 30 days prior to or
             received TZP-101 within 90 days prior to study initiation

          -  Subject is pregnant or is breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Indiana Gastroenterology Group</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <zip>46016-4346</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amrita Institute of Medical Sciences Research Center (AIMS)</name>
      <address>
        <city>Cochin</city>
        <state>Kerala</state>
        <zip>682026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <zip>M139WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S102JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>India</country>
    <country>Norway</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2008</study_first_submitted>
  <study_first_submitted_qc>February 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2008</study_first_posted>
  <disposition_first_submitted>December 5, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>December 5, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 7, 2012</disposition_first_posted>
  <last_update_submitted>December 5, 2012</last_update_submitted>
  <last_update_submitted_qc>December 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>delayed gastric emptying</keyword>
  <keyword>symptomatic gastroparesis</keyword>
  <keyword>diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

